MAJOR DEPRESSIVE DISORDER TREATMENT MARKET ANALYSIS

Global Major Depressive Disorder (MDD) Treatment Market, By Product Type (Drug Type (Antidepressants, Atypical antidepressants, and Antipsychotics), Neuromodulator, and Stem Cell Therapy), and by Geography- Global Industry Insights, Trends, Outlook, And Opportunity Analysis, 2022-2028

To Be Published : Oct 2024
Code : CMI1217
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

North America is expected to be dominant in the market over the forecast period, owing to increasing prevalence of major depressive disorder

North America is expected to be dominant in major depressive disorder treatment market due to increasing prevalence of MDD in the U.S. For instance, according to National Institute of Mental Health In 2015, an estimated 16.1 million adults aged 18 or elder in the U.S. had at least one major depressive episode in the past year, representing 6.7% of all the U.S. adults. Europe is expected to be the second largest market for major depressive disorder treatment due to rapid approval of new therapies from regulatory bodies. For instance in 2015, Soterix Medical received CE Marking for its new tDCS depressive disorder therapy used for the treatment of MDD.